Gallbladder cancer market Analysis

Gallbladder cancer market

Gallbladder Cancer Market, By Treatment Type (Surgery, Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, and Others), By Cancer Type (Adenocarcinoma, Squamous cell carcinoma, Adenosquamous carcinoma, Small cell carcinoma, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

  • Nov 2023
  • CMI6243
  • 150 Pages
  • Excel & Pdf
  • Pharmaceutical

The global gallbladder cancer market size is projected to reach US$ 100.1 million by 2030, from US$ 73.5 million in 2023, at a CAGR of 4.5% during the forecast period. The increasing prevalence of gallbladder cancer is anticipated to increase the demand for treatment, subsequently driving the growth of the global gallbladder cancer treatment market. This combined with the rising adoption of minimally invasive surgical procedures and the growing focus on research and development of novel treatment options are expected to propel the market growth in the coming years.

Gallbladder Cancer Market Regional Insights

  • North America is expected to be the largest market for gallbladder cancer during the forecast period, accounting for over 37% of the market share in 2023. The growth of the market in North America is attributed to the rising incidence of gallbladder cancer, presence of key players, and availability of advanced healthcare infrastructure in the region.
  • The Europe market is expected to be the second-largest market for gallbladder cancer, accounting for over 28% of the market share in 2023. The growth of the market in Europe is attributed to the high healthcare expenditure and growing research on novel therapeutics in the region.
  • The Asia Pacific market is expected to be the fastest-growing market for gallbladder cancer, with a CAGR of 6.2% over during the forecast period. The growth of the market in Asia Pacific is attributed to the large undiagnosed patient pool, improving healthcare infrastructure, and increasing awareness programs by governments and nongovernmental organization (NGO) in the region.

Figure 1. Global Gallbladder Cancer Market Share (%), by Region, 2023

Analysts’ Views on the Global Gallbladder Cancer Market:

Gallbladder cancer is a serious condition with high mortality rates. It is more common in women and older adults. The market for gallbladder cancer includes various treatment modalities such as surgery, radiation therapy, and chemotherapy. The global gallbladder cancer market is expected to witness significant growth in the coming years. This growth is primarily driven by the increasing prevalence of gallbladder cancer worldwide, advancements in diagnostic technologies, and the development of novel therapeutics.

Gallbladder Cancer Market Drivers

  • Increasing prevalence of gallbladder cancer: The rising incidence of gallbladder cancer globally is a major factor driving growth in the gallbladder cancer market. Gallbladder cancer is a relatively rare cancer, but rates have been slowly rising over the past few decades. For instance, according to data published by the Cancer Council Victoria in 2021, 288 Victorians were diagnosed with gallbladder cancer. Of these, there were 140 males and 148 females.
  • Growing geriatric population: The gallbladder cancer market is also driven by the growing geriatric population across the globe. Gallbladder cancer usually affects older adults and incidence rates peak in the sixth and seventh decade of life. According to the United Nations, the global population aged 65 years or over is projected to grow from 727 million in 2020 to around 50 billion in 2050. The rapidly aging global population is therefore expected to drive the increasing demand for gallbladder cancer diagnostics and treatments.

Gallbladder Cancer Market Opportunities

  • Huge unmet needs: There is lot of unmet need in the gallbladder cancer market. For instance, according to the data published by the American Society of Clinical Oncology (ASCO), it is estimated that 4,510 deaths (1,900 men and 2,610 female) from gallbladder and other biliary cancers will occur in the U.S. in 2023.

Gallbladder Cancer Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2023: US$ 73.5 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 4.5% 2030 Value Projection: US$ 100.1 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East:  GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa 
Segments covered:
  • By Treatment Type: Surgery, Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, and Others 
  • By Cancer Type: Adenocarcinoma, Squamous cell carcinoma, Adenosquamous carcinoma, Small cell carcinoma, and Others
  • By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others
Companies covered:

Eli Lilly and Company, Bristol-Myers Squibb, Roche, Pfizer, Novartis, Merck & Co., Inc., Sanofi, AstraZeneca, AbbVie, and Gilead 

Growth Drivers:
  • Increasing prevalence of gallbladder cancer
  • Growing geriatric population
  • Advancements in cancer treatment technologies
  • Rising healthcare expenditure
Restraints & Challenges:
  • High cost burden of cancer therapies
  • Adverse effects of treatment
  • Lack of approved targeted therapies

Gallbladder Cancer Market Trends

  • Increasing research and development activities by the market players: Increasing research and development activities by the market players are expected to propel the market growth over the forecast period. For instance, on September 5, 2022, AstraZeneca, a pharmaceutical company, has received approval for Imfinzi (durvalumab) in the U.S. for the treatment of adult patients with locally advanced or metastatic biliary tract cancer in combination with chemotherapy.

Gallbladder Cancer Market Restraints

  • High cost burden of cancer therapies: For example, according to statistics from the World Health Organization (WHO), gallbladder and biliary tract cancers are among the 10 most expensive cancers to treat in terms of initial workup and primary treatment costs. A surgery to remove the gallbladder (cholecystectomy) alone costs anywhere between US$ 20,000 to US$ 50,000 depending on the extent of surgery and hospitalization charges in different countries. Add to this the costs of pre-surgical tests like CT scans, MRIs, or biopsies which can cumulatively exceed US $10,000. Post-surgery, patients also require chemotherapy and radiation sessions. On an average, a single cycle of some of the commonly used chemotherapy drugs like gemcitabine costs US$ 3,000 to US$ 10,000. Radiation therapy sessions cost US$ 100 to US$ 500 per session and patients typically require 20 to 30 sessions. Prolonged hospital stays further add to the costs.
  • Lack of approved targeted therapies: Despite research into molecular alterations in gallbladder cancer, limited targeted agents have received US FDA or European Medicines Agency (EMA) approval specifically for this indication. For instance, only one FGFR inhibitor pemigatinib has been approved so far despite the prevalence of FGFR fusions. Moreover, genomic testing to identify potential targets is also not widely adopted yet. Lack of regulatory approved targeted therapies tailored for advanced gallbladder cancer cases hinders market growth currently.

Recent Developments

  • On October 21, 2023, Regeneron Pharmaceuticals, Inc., a pharmaceutical company, announced the first presentation of key secondary endpoints for an investigational regimen of PD-1 inhibitor Libtayo (cemiplimab) as a neoadjuvant monotherapy in stage II to IV resectable Cutaneous Squamous Cell Carcinoma (CSCC)
  • In June 2023, Sirnaomics Ltd., a biopharmaceutical company, announced the advancement of STP705 for the treatment of Squamous Cell Carcinoma (isSCC) in situ into late-stage clinical development

Acquisition and partnerships

  • On August 1, 2023, Replimune Group, Inc., a clinical stage biotechnology company, and Incyte, a global biopharmaceutical company, announced a clinical trial collaboration and supply agreement to study RP1, Replimune Group, Inc. lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor

Figure 2. Global Gallbladder Cancer Market Share (%), by Cancer Type, 2023

Top Companies in the Gallbladder Cancer Market

  • Eli Lilly and Company
  • Bristol-Myers Squibb
  • Roche
  • Pfizer
  • Novartis
  • Merck & Co., Inc.
  • Sanofi
  • AstraZeneca
  • AbbVie
  • Gilead Sciences

Definition: The gallbladder cancer market refers to the market and ecosystem centered around diagnosing and treating cancer that develops in the gallbladder. Gallbladder cancer is a relatively uncommon but a highly fatal disease. It most commonly takes the form of adenocarcinomas developing from the epithelial cells of the gallbladder. Diagnosis typically involves imaging tests like ultrasound, CT, MRI along with blood tests and biopsy. Treatment options include surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapies.

Few Other Promising Reports in Pharmaceuticals Industry

Lung cancer surgery market

Cancer Biopsy Market

Cancer Drugs Market

Pituitary Cancer Market

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Gallbladder Cancer Market, By Treatment Type
      • Gallbladder Cancer Market, By Cancer Type
      • Gallbladder Cancer Market, By Distribution Channel
      • Gallbladder Cancer Market, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Increasing prevalence of gallbladder cancer
      • High cost burden of cancer therapies
      • Development of targeted therapies
    • Impact Analysis
    • Key Highlights
    • Regulatory Scenario
    • Product Launches/Approvals
    • PEST Analysis
    • PORTER’s Analysis
    • Merger and Acquisition Scenario
  4. Gallbladder Cancer Market - Impact of Coronavirus (COVID-19) Pandemic
    • COVID-19 Epidemiology
    • Supply Side and Demand Side Analysis
    • Economic Impact
  5. Gallbladder Cancer Market, By Treatment Type, 2018-2030, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2019 - 2030
      • Segment Trends
    • Surgery
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Chemotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Radiation Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Immunotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Targeted Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  6. Gallbladder Cancer Market, By Cancer Type, 2018-2030, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2030 (%)
      • Y-o-Y Growth Analysis, 2019 - 2030
      • Segment Trends
    • Adenocarcinoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Squamous cell carcinoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Adenosquamous carcinoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Small cell carcinoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
  7. Gallbladder Cancer Market, By Distribution Channel, 2018-2030, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2030 (%)
      • Y-o-Y Growth Analysis, 2019 - 2030
      • Segment Trends
    • Hospital Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Retail Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Online Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
  8. Gallbladder Cancer Market, By Region, 2018-2030, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Country, 2018 and 2030 (%)
      • Y-o-Y Growth Analysis, For Country 2019 - 2030
      • Country Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
        • U.K.
        • Germany
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Region/Country, 2018-2030, (US$ Mn)
        • South Africa
        • North Africa
        • Central Africa
  9. Competitive Landscape
    • Eli Lilly and Company
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Bristol-Myers Squibb
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Roche
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Pfizer
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Novartis
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Merck & Co., Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Sanofi
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • AstraZeneca
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • AbbVie
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Gilead Sciences
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Analyst Views
  10. Section
    • Research Methodology
    • About us

*Browse 35 market data tables and 37 figures on “Gallbladder Cancer Market” - Global forecast to 2030

Detailed Segmentation:

  • By Treatment Type
    • Surgery
    • Chemotherapy
    • Radiation Therapy
    • Immunotherapy
    • Targeted Therapy
    • Others
  • By Cancer Type
    • Adenocarcinoma
    • Squamous cell carcinoma
    • Adenosquamous carcinoma
    • Small cell carcinoma
    • Undifferentiated carcinoma
    • Others
  • By Distribution Channel
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • Others
  • By Region
    • North America
    • Europe
    • APAC
    • Latin America
    • Middle East
    • Africa
- Frequently Asked Questions -

What are the key factors hampering the growth of the gallbladder cancer market?

Limited approved therapies for the treatment of gallbladder cancer methods hamper the growth of the Gallbladder Cancer Market.

What are the major factors driving the gallbladder cancer market growth?

Increasing incidence of gallbladder cancer is expected to propel the market growth over the forecast period

Which is the leading segment in the gallbladder cancer market?

The leading segment in the Gallbladder Cancer Market is the surgery segment accounts for the largest market share.

Which are the major players operating in the gallbladder cancer market?

The major market players operating in the market includes Eli Lilly and Company, Bristol-Myers Squibb, Roche, Pfizer, Novartis, Merck & Co., Inc., Sanofi, AstraZeneca, AbbVie, Gilead Sciences

Which region will lead the Market?

North America is expected to lead the gallbladder cancer market due to increasing prevalence of gallbladder cancer in the region.
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.